About
Imbruvica (Ibrutinib) 140mg Capsule is an advanced, targeted oral therapy categorized as a Bruton's tyrosine kinase (BTK) inhibitor. Its mechanism of action involves forming a strong, irreversible covalent bond with a specific cysteine residue within the BTK active site, leading to sustained inhibition of BTK activity. This crucial inhibition effectively disrupts the B-cell receptor signaling pathway, which is fundamentally essential for the survival, proliferation, and migration of malignant B-cells implicated in various lymphomas and leukemias. Imbruvica represents a transformative therapeutic option for patients diagnosed with specific B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). By selectively interfering with these critical cancer cell growth and survival mechanisms, it provides a highly targeted approach that can lead to durable responses, improved progression-free survival, and enhanced quality of life for eligible patients, often offering an alternative to conventional chemotherapy regimens.
Uses
- Chronic Lymphocytic Leukemia (CLL)
- Mantle Cell Lymphoma (MCL)
- Waldenström's Macroglobulinemia (WM)
- Marginal Zone Lymphoma (MZL)
Directions For Use
Take orally once daily with a glass of water, at approximately the same time each day. Do not open, break, or chew the capsules.
Benefits
- Targeted cancer therapy
- Improved progression-free survival
- Oral administration convenience
- Reduced need for traditional chemotherapy
- Effective in relapsed/refractory cases
- Manageable side effect profile
Side Effects
- Diarrhea
- Fatigue
- Nausea
- Musculoskeletal pain
- Rash
- Bruising
- Bleeding (minor to severe)
- Atrial fibrillation
- Hypertension
- Infections
- Neutropenia
- Thrombocytopenia
Safety Measures
- Alcohol - Avoid or limit alcohol consumption due to potential for increased bleeding risk and possible liver strain.
- Pregnancy - Contraindicated during pregnancy due to potential for fetal harm. Use effective contraception during treatment and for a period after.
- Breastfeeding - Contraindicated during breastfeeding as it is unknown if Ibrutinib is excreted in human milk, but potential for serious adverse reactions in infants exists.
- Liver - Dose adjustment is required in patients with hepatic impairment. Monitor liver function closely during treatment.
- Kidney - No specific dose adjustment for mild to moderate renal impairment; use with caution in severe impairment.
- Lung - Monitor for new or worsening pulmonary symptoms; interstitial lung disease has been reported with Ibrutinib.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!